Suscribirse

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. - 31/08/22

Doi : 10.1016/j.biopha.2022.113499 
Yasser Mohamed a, b , Yousra A. El-Maradny a, c , Ahmed K. Saleh d, AbdElAziz A. Nayl e, , Hamada El-Gendi f, , Esmail M. El-Fakharany a,
a Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg EL-Arab, Alexandria 21934, Egypt 
b Laboratory of Kafr El-Sheikh Fever Hospital, Kafr El-Sheikh Fever Hospital, 33511 Kafr El-Sheikh, Egypt 
c Microbiology Department, High Institute of Public Health, Alexandria University, Alexandria 21526, Egypt 
d Cellulose and Paper Department, National Research Centre, El-Tahrir St., Dokki, P.O. 12622, Giza, Egypt 
e Department of Chemistry, College of Science, Jouf University, Sakaka 72341, Al Jouf, Saudi Arabia 
f Bioprocess Development Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Universities and Research Institutes zone, New Borg El-Arab, Alexandria 21934, Egypt 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

The healthy immune system eliminates pathogens and maintains tissue homeostasis through extraordinarily complex networks with feedback systems while avoiding potentially massive tissue destruction. Many parameters influence humoral and cellular vaccine responses, including intrinsic and extrinsic, environmental, and behavioral, nutritional, perinatal and administrative parameters. The relative contributions of persisting antibodies and immune memory as well as the determinants of immune memory induction, to protect against specific diseases are the main parameters of long-term vaccine efficacy. Natural and vaccine-induced immunity and monoclonal antibody immunotherapeutic, may be evaded by SARS-CoV-2 variants. Besides the complications of the production of COVID-19 vaccinations, there is no effective single treatment against COVID-19. However, administration of a combined treatment at different stages of COVID-19 infection may offer some cure assistance. Combination treatment of antiviral drugs and immunomodulatory drugs may reduce inflammation in critical COVID-19 patients with cytokine release syndrome. Molnupiravir, remdesivir and paxlovid are the approved antiviral agents that may reduce the recovery time. In addition, immunomodulatory drugs such as lactoferrin and monoclonal antibodies are used to control inflammatory responses in their respective auto-immune conditions. Therefore, the widespread occurrence of highly transmissible variants like Delta and Omicron indicates that there is still a lot of work to be done in designing efficient vaccines and medicines for COVID-19. In this review, we briefly discussed the immunological response against SARS-CoV-2 and the vaccines approved by the World Health Organization (WHO) for COVID-19, their mechanisms, and side effects. Moreover, we mentioned various treatment trials and strategies for COVID-19.

El texto completo de este artículo está disponible en PDF.

Graphical Abstract




ga1

El texto completo de este artículo está disponible en PDF.

Highlights

Available vaccines and treatments in COVID-19 management of, including their effect against SARS-CoV-2 variants of concern.
Some vaccines against SARS-CoV-2 are under emergency approval, and the mRNA vaccine shows the most effective technique.
Paxlovid, molnupiravir, and remdesivir are the currently effective antiviral agents against Omicron subvariants of SARS-CoV-2.
Bebtelovimab is the only monoclonal antibody that is active against all Omicron subvariants.
Some supportive treatments against SARS-CoV-2 such as lactoferrin show immunomodulatory and anti-inflammatory effects.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Antiviral, Immunomodulators, Vaccination, Treatment

Abbreviations : +ssRNA, 3CL, ACE2, CCCs, ChAd, CRS, DPP, GRAS, HSPGs, IL-6, mAb, miRNA, PAMPs, PRRs, RdRp, SARS-CoV-2, SSRI, Th, TLRs, Tregs, VLPs, VOCs


Esquema


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 153

Artículo 113499- septembre 2022 Regresar al número
Artículo precedente Artículo precedente
  • ZEB1: Catalyst of immune escape during tumor metastasis
  • Jiahui Lu, Fei Fei, Chenxi Wu, Jie Mei, Junying Xu, Peihua Lu
| Artículo siguiente Artículo siguiente
  • Spatiotemporal dynamics of the cellular components involved in glial scar formation following spinal cord injury
  • Ce Zhang, Jianning Kang, Xiaodi Zhang, Ying Zhang, Nana Huang, Bin Ning

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.